China Oncology ›› 2023, Vol. 33 ›› Issue (4): 368-376.doi: 10.19401/j.cnki.1007-3639.2023.04.007
• Article • Previous Articles Next Articles
PENG Jin(), WANG Weining(), TAN Zhi, YE Guannan, ZHOU Zhen
Received:
2022-04-03
Revised:
2023-03-07
Online:
2023-04-30
Published:
2023-05-15
Contact:
WANG Weining
CLC Number:
PENG Jin, WANG Weining, TAN Zhi, YE Guannan, ZHOU Zhen. The mechanism of m6Am-modifying enzyme PCIF1 regulating target gene ACOT8 in gastric cancer progression[J]. China Oncology, 2023, 33(4): 368-376.
Fig. 1
Expression of PCIF1 in gastric cancer tissues and cells A: The expressions of PCIF1 in gastric cancer tissues and normal control tissues were evaluated by GEPIA database; B: The relative expression levels of PCIF1 in para-cancerous tissues (P) and gastric cancer tissues (T) were examined by Western blot; C: The relative expression levels of PCIF1 in gastric cancer tissues and non-gastric cancer tissues were examined by RTFQ-PCR; D: GEPIA database analysis revealed that the high expression of PCIF1 indicated that the overall survival prediction of gastric cancer patients was better; E: The expression level of PCIF1 in gastric cancer cell lines was examined by Western blot. **: P<0.01, compared with para-cancerous tissues."
Fig. 2
Knockout PCIF1 inhibits the proliferation, migration and invasion of gastric cancer in vitro A: RTFQ-PCR was used to evaluate the expression of PCIF1 knocked down by shRNA in SNU5 cells; B: CCK-8 assay was performed to evaluate the viability of SNU5 cells silenced by PCIF1; C: EdU assay was performed to evaluate the proliferation ability of SNU5 cells silenced by PCIF1; D-F: The effect of PCIF1 knock-down on migration and invasion of SNU5 cells was detected by transwell assay. *: P<0.05, compared with sh-NC group; **: P<0.01, compared with sh-NC group; ***: P<0.001, compared with sh-NC group."
Fig.3
PCIF1 promotes the proliferation, migration and invasion of gastric cancer in vitro A: RTFQ-PCR was used to evaluate the expression of PCIF1 upregulated by lentivirus in AGS cells; B: CCK-8 assay was performed to evaluate the activity of AGS cells up-regulated by PCIF1; C: EdU assay was performed to evaluate the proliferation ability of AGS cells up-regulated by PCIF1; D-F: Transwell was used to detect the effect of PCIF1 upregulation on the migration and invasion of AGS cells. *: P<0.05, compared with NC group;**: P<0.01, compared with NC group; ***: P<0.001, compared with NC group."
Fig. 4
PCIF1 regulates the expression of ACOT8 in gastric cancer A: The correlation between PCIF1 and ACOT8 expression was analyzed by GEPIA database. B: RTFQ-PCR was used to evaluate the effect of overexpressing PCIF1 on ACOT8 expression in AGS cells (***: P<0.001, compared with NC group). C: RIP-qPCR was used to detect the enrichment of PCIF1 combined with ACOT8 in AGS cells (*: P<0.05, compared with IgG in NC group; #: P<0.05, compared with sh-PCIF1 in NC group). D: Overexpression of PCIF1 prolonged the half-life of ACOT8 mRNA in AGS cells (*: P<0.05, compared with NC group)."
Fig. 5
PCIF1 exerts its tumor-promoting effect through ACOT8 A: RTFQ-PCR was used to confirm the efficiency of sh-ACOT8 in PCIF1 overexpressing AGS cells; B: CCK-8 assay was performed to assess the effect of ACOT8 silencing on the proliferative capacity of PCIF1 overexpressing AGS cells; C: EdU analysis of the effect of ACOT8 silencing on the proliferation of PCIF1 overexpressing AGS cells; D-F: Transwell assessment of the effect of ACOT8 silencing on migration and invasion of PCIF1 overexpressing AGS cells. *: P<0.05, compared with NC group;**: P<0.01, compared with NC group;***: P<0.001, compared with NC group; #: P<0.05, compared with PCIF1 group; ##: P<0.01, compared with PCIF1 group; ###: P<0.001, compared with PCIF1 group."
Fig. 6
PCIF1 promotes the growth of gastric cancer in vivo A: Representative tumors after transplantation of PCIF1 overexpression or negative control AGS cells into nude mice; B: Comparison of tumor volumes in PCIF1 overexpressing or negative AGS cell transplanted tumor nude mice; C: Comparison of tumor weights; D: Expression levels of PCIF1 and ACOT8 in tumor tissues were determined using immunohistochemistry. *: P<0.05, compared with NC group; **: P<0.01, compared with NC group."
[1] |
SHIMURA T, KANDIMALLA R, OKUGAWA Y, et al. Novel evidence for m6A methylation regulators as prognostic biomarkers and FTO as a potential therapeutic target in gastric cancer[J]. Br J Cancer, 2022, 126(2): 228-237.
doi: 10.1038/s41416-021-01581-w |
[2] |
RAY K. New markers and models of premalignancy and the early development of gastric cancer[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(4): 193.
doi: 10.1038/s41575-020-0280-1 pmid: 32103202 |
[3] | 杨敏, 赵国林, 张东伟. N6-甲基腺苷修饰在肿瘤及病毒感染中的研究进展[J]. 中华实验外科杂志, 2021, 38(4): 774-777. |
YANG M, ZHAO G L, ZHANG D W. Research progress of N6-methyladenosine modification in tumor and virus infection[J]. Chin J Exp Surg, 2021, 38(4): 774-777. | |
[4] |
TAN B, LIU H, ZHANG S Y, et al. Viral and cellular N6-methyladenosine and N6, 2'-O-dimethyladenosine epitranscriptomes in the KSHV life cycle[J]. Nat Microbiol, 2018, 3(1): 108-120.
doi: 10.1038/s41564-017-0056-8 |
[5] | TARTELL M A, BOULIAS K, HOFFMANN G B, et al. Methylation of viral mRNA cap structures by PCIF1 attenuates the antiviral activity of interferon-Β[J]. Proc Natl Acad Sci U S A, 2021, 118(29): e2025769118. |
[6] |
RELIER S, RIPOLL J, GUILLORIT H, et al. FTO-mediated cytoplasmic m6Am demethylation adjusts stem-like properties in colorectal cancer cell[J]. Nat Commun, 2021, 12(1): 1716.
doi: 10.1038/s41467-021-21758-4 |
[7] |
ZHUO W, SUN M, WANG K, et al. m6Am methyltransferase PCIF1 is essential for aggressiveness of gastric cancer cells by inhibiting TM9SF1 mRNA translation[J]. Cell Discov, 2022, 8(1): 48.
doi: 10.1038/s41421-022-00395-1 |
[8] |
WU W Z, ZHANG F, ZHAO J, et al. The N6-methyladenosine: mechanisms, diagnostic value, immunotherapy prospects and challenges in gastric cancer[J]. Exp Cell Res, 2022, 415(2): 113115.
doi: 10.1016/j.yexcr.2022.113115 |
[9] |
GAO S F, ZHOU J B, HU Z Y, et al. Effects of the m6Am methyltransferase PCIF1 on cell proliferation and survival in gliomas[J]. Biochim Biophys Acta Mol Basis Dis, 2022, 1868(11): 166498.
doi: 10.1016/j.bbadis.2022.166498 |
[10] |
LUO Q, MO J Z, CHEN H, et al. Structural insights into molecular mechanism for N6-adenosine methylation by MT-A70 family methyltransferase METTL4[J]. Nat Commun, 2022, 13(1): 5636.
doi: 10.1038/s41467-022-33277-x |
[11] |
XIE S S, CHEN W W, CHEN K H, et al. Emerging roles of RNA methylation in gastrointestinal cancers[J]. Cancer Cell Int, 2020, 20(1): 585.
doi: 10.1186/s12935-020-01679-w pmid: 33372610 |
[12] |
LI Q H, HE W L, WAN G H. Methyladenosine modification in RNAs: classification and roles in gastrointestinal cancers[J]. Front Oncol, 2020, 10: 586789.
doi: 10.3389/fonc.2020.586789 |
[13] |
JIN M Z, ZHANG Y G, JIN W L, et al. A pan-cancer analysis of the oncogenic and immunogenic role of m6Am methyltransferase PCIF1[J]. Front Oncol, 2021, 11: 753393.
doi: 10.3389/fonc.2021.753393 |
[14] |
PALMEIRA J D F, ARGAÑARAZ G A, DE OLIVEIRA G X L M, et al. Physiological relevance of ACOT8-Nef interaction in HIV infection[J]. Rev Med Virol, 2019, 29(5): e2057.
doi: 10.1002/rmv.2057 |
[15] |
GHARIB E, NASRINASRABADI P, ZALI M R. Development and validation of a lipogenic genes panel for diagnosis and recurrence of colorectal cancer[J]. PLoS One, 2020, 15(3): e0229864.
doi: 10.1371/journal.pone.0229864 |
[16] |
YOU B J, CHEN L Y, HSU P H, et al. Orlistat displays antitumor activity and enhances the efficacy of paclitaxel in human hepatoma Hep3B cells[J]. Chem Res Toxicol, 2019, 32(2): 255-264.
doi: 10.1021/acs.chemrestox.8b00269 |
[17] |
BOULIAS K, TOCZYDŁOWSKA-SOCHA D, HAWLEY B R, et al. Identification of the m6Am methyltransferase PCIF1 reveals the location and functions of m6Am in the transcriptome[J]. Mol Cell, 2019, 75(3): 631-643.e8.
doi: 10.1016/j.molcel.2019.06.006 |
[18] |
SUN H X, ZHANG M L, LI K, et al. Cap-specific, terminal N6-methylation by a mammalian m6Am methyltransferase[J]. Cell Res, 2019, 29(1): 80-82.
doi: 10.1038/s41422-018-0117-4 |
[1] | JIANG Jinling, ZHOU Chenfei, WANG Chao, ZHAO Liqin, WU Junwei, ZHANG Jun. Advanced progress in research and diagnosis of gastric cancer in 2022 [J]. China Oncology, 2023, 33(4): 303-314. |
[2] | XIAO Lanshu, PAN Liudi, LIU Yi, WANG Jie, CHEN Hui. LncRNA DLEU7-AS1 contributes to proliferation and migration of gastric cancer by regulating MSN transcription [J]. China Oncology, 2023, 33(4): 327-341. |
[3] | CHEN Hong, CHEN Junxia. Effect of hsa_circ_0001573 on biological behaviors of breast cancer cells and its molecular mechanism [J]. China Oncology, 2023, 33(4): 342-353. |
[4] | LIU Yang, HU Yiyang, LIU Yueping, NIU Shuyao, DING Pingan, TIAN Yuan, GUO Honghai, YANG Peigang, ZHANG Ze, ZHENG Tao, TAN Bibo, FAN Liqiao, LI Yong, ZHAO Qun. The value of artificial intelligence-assisted technology in HER2 assessmentof gastric cancer patients receiving neoadjuvant chemotherapy [J]. China Oncology, 2023, 33(4): 377-387. |
[5] | FU Qingsheng, JIN Lei, ZHANG Xudong, XU Yingchen, ZHU Chunfu, QIN Xihu, WU Baoqiang. Effect of tRF-Pro-CGG on the biological behavior of mouse pancreatic cancer cells and its molecular mechanism [J]. China Oncology, 2023, 33(3): 241-249. |
[6] | LENG Jie, QIU Guochun, ZHANG Bo, PU Yan. Mechanism of breast cancer centrosome regulatory protein SEC23B on tumor invasion and metastasis [J]. China Oncology, 2023, 33(2): 152-161. |
[7] | CHEN Xinning, JIANG Huiqin, YANG Yihui, YU Qian, ZHANG Chunyan, WANG Beili, PAN Baishen, GUO Wei. Expression of plasma methylated Septin9 gene and its clinical significance in patients with gastric cancer [J]. China Oncology, 2023, 33(2): 162-167. |
[8] | WANG Xiaoxiao, CHEN Xi, LI Minmin, SONG Ning, SUN Dongyuan, JIANG Yingying. Effects of NOL8 on cell proliferation, migration and invasion of oral squamous cell carcinoma [J]. China Oncology, 2023, 33(1): 45-53. |
[9] | LIU Xueping, MU Nai, LI Xiaochun, WANG Ruisi, TAN Bangxian. Gingival metastasis from primary hepatocellular carcinoma: a case report [J]. China Oncology, 2023, 33(1): 78-80. |
[10] | YU Hang, LIU Wensheng, ZHANG Ning, LIU Haikuan, CHEN Luohai, YAO Wang, FAN Wenzhe, LI Jiaping, CHEN Jie, WANG Yu. The efficacy and safety analysis of transarterial embolization in the treatment of cystic neuroendocrine neoplasm liver metastasis [J]. China Oncology, 2022, 32(9): 794-799. |
[11] | ZHENG Xiuli, YAO Zhiyuan, WU Mingli, ER Limian, LI Shengmian. Analysis of risk factors of lymph node metastasis and comparison of endoscopic resection methods in rectal neuroendocrine neoplasm [J]. China Oncology, 2022, 32(9): 800-806. |
[12] | ZHANG Jingchen, LI Xin, LI Jiangtao, LI Haiping, CHEN Yanli, NIU Bing, QI Chuanchuan, YE Beibei. LINC02163 targeting miR-338-3p affects proliferation, invasion and migration of breast cancer cells [J]. China Oncology, 2022, 32(9): 818-826. |
[13] | CAI Gang, WANG Shubei, CHEN Jiayi. The current data and challenge of radiotherapy in the case management of gastric cancer [J]. China Oncology, 2022, 32(7): 581-587. |
[14] | CAO Mengxuan, HU Can, ZHANG Yanqiang, HUANG Ling, DU Yian, YU Pengcheng, ZHANG Ruolan, XU Zhiyuan, CHENG Xiangdong. Analysis of risk factors of early recurrence and metastasis after radical resection of gastric cancer [J]. China Oncology, 2022, 32(7): 588-595. |
[15] | JIANG Jinling, ZHOU Chenfei, XI Wenqi, SHI Min, GEN Mei, ZHAO Liqin, CAI Qu, JIANG Jinsong, ZHANG Jun. Optimization of 5-FU metronomic chemotherapy strategy and regulation of the immune microenvironment in gastric cancer: an in vivo study [J]. China Oncology, 2022, 32(7): 596-605. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd